PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
London S.E.
18:35:04 02/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 107.80 GBX | -2.53% |
|
-5.77% | -13.76% |
| 09-09 | EARNINGS AND TRADING: Pebble Beach revenue grows as forecast | AN |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| Market Cap | 350M 311M 290M 264M 498M 33.62B 503M 3.51B 1.36B 17.18B 1.31B 1.28B 55.15B | P/E 2026 * |
-3.02x | P/E 2027 * | -3.06x |
|---|---|---|---|---|---|
| Enterprise Value | 76.2M 67.71M 63.19M 57.6M 109M 7.33B 110M 765M 296M 3.74B 286M 280M 12.02B | EV / Sales 2026 * |
9.71x | EV / Sales 2027 * | 8.83x |
| Free-Float |
84.97% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| PRTC | Delayed | |
CBOE
| PRTC | Real-time | |
|
Xetra
| 0VQ | End-of-day quote | |
|
OTC Markets
| PTCHF | Delayed | |
|
Deutsche Boerse AG
| 0VQ | Delayed | |
|
Börse Stuttgart
| 0VQ | Delayed |
Last Transcript: PureTech Health plc
| 1 day | -2.53% | ||
| 1 week | -5.77% | ||
| Current month | -6.26% | ||
| 1 month | -14.44% | ||
| 3 months | -10.32% | ||
| 6 months | -4.60% | ||
| Current year | -13.76% |
| 1 week | 107.2 |  | 118.6 |
| 1 month | 107.2 | | 127 |
| Current year | 107.2 | | 143.6 |
| 1 year | 107.2 | | 143.6 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 375.5 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/13/26 A | Buy | Founder | 112,509 | 0.0466% | ||
| 9/24/25 A | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 9/24/25 A | Buy | Director | 29,239 | 0.0122% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.53% | -5.77% | -23.65% | -35.45% | 350M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | |
| Average | -0.46% | -1.11% | +45.01% | +112.14% | 39.09B | |
| Weighted average by Cap. | +0.12% | -0.84% | +56.89% | +138.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.85M 6.97M 6.51M 5.93M 11.19M 755M 11.29M 78.77M 30.52M 386M 29.47M 28.83M 1.24B | 14.01M 12.45M 11.62M 10.59M 19.98M 1.35B 20.16M 141M 54.49M 689M 52.61M 51.47M 2.21B |
| Net income | -135M -120M -112M -102M -192M -12.94B -194M -1.35B -524M -6.62B -506M -495M -21.24B | -119M -106M -98.72M -89.98M -170M -11.44B -171M -1.19B -463M -5.85B -447M -437M -18.78B |
| Net Debt | -273M -243M -227M -207M -390M -26.29B -393M -2.74B -1.06B -13.44B -1.03B -1B -43.13B | -226M -201M -187M -171M -322M -21.73B -325M -2.27B -879M -11.11B -848M -830M -35.64B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | GBX 107.80 | -2.53% | 856,828 |
| 01/10/26 | GBX 110.60 | -3.83% | 411,805 |
| 30/09/26 | GBX 115.00 | +0.70% | 758,823 |
| 29/09/26 | GBX 114.20 | -1.21% | 282,714 |
| 28/09/26 | GBX 115.60 | +1.05% | 740,403 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
